RNA therapeutics inhibit the expression of specific proteins/RNAs by targeting complementary sequences of corresponding genes or encode proteins for the synthesis desired genes to treat genetic diseases. RNA-based therapeutics are categorized as oligonucleotide drugs (antisense oligonucleotides, small interfering RNA, RNA aptamers), and mRNA drugs. The antisense oligonucleotides and small interfering RNA for treatment of genetic diseases have been approved by the FDA in the United States, while RNA aptamers and mRNA drugs are still in clinical trials. Chemical modifications can be applied to RNA drugs, such as pseudouridine modification of mRNA, to reduce immunogenicity and improve the efficacy. The secure and effective delivery systems such as lipid-based nanoparticles, extracellular vesicles, and virus-like particles are under development to address stability, specificity, and safety issues of RNA drugs. This article provides an overview of the specific molecular mechanisms of eleven RNA drugs currently used for treating genetic diseases, and discusses the research progress of chemical modifications and delivery systems of RNA drugs.
Aptamers, Nucleotide ; RNA, Small Interfering/therapeutic use* ; RNA, Messenger ; Oligonucleotides, Antisense/therapeutic use*

Dengue virus infection has become a global threat affecting around 100 countries in the world. Currently, there is no licensed antiviral agent available against dengue. Thus, there is a strong need to develop therapeutic strategies that can tackle this life threatening disease. RNA interference is an important and effective gene silencing process which degrades targeted RNA by a sequence specific process. Several studies have been conducted during the last decade to evaluate the efficiency of siRNA in inhibiting dengue virus replication. This review summarizes siRNAs as a therapeutic approach against dengue virus serotypes and concludes that siRNAs against virus and host genes can be next generation treatment of dengue virus infection.
Animals ; Dengue ; therapy ; Dengue Virus ; genetics ; Humans ; RNA Interference ; RNA, Small Interfering ; genetics ; therapeutic use

As the discovery of RNA interference (RNAi) and the gradual conquering of a series of technical issues, a few of RNAi therapeutics have been approved in the non-tumor field abroad. With the advantages of high specificity, long duration of efficacy, and high success rate of development, RNAi therapeutics have become the emerging field globally. There are no RNAi therapeutics approved in oncology so far, and people are hoping a breakthrough in the field. In the present article, the characteristics and potential anti-tumor mechanism of RNAi therapeutics, difficulties in delivery system and progress in oncology are described, and the potential reasons why their success in non-tumor field is difficult to be simply replicated in tumor field are analyzed, providing reference for research and clinical transformation of RNAi therapeutics in oncology.
.
Humans ; Lung Neoplasms/genetics* ; RNA Interference ; RNA, Small Interfering/therapeutic use*

It has been reviewed that as many as hundreds genes are dysregulated in various kinds of cancers, yet most therapies are targeted toward a single gene. Recently, the mode of cancer treatment has been changed by a shift in thinking from mono-target to multi-target therapies. There is considerable evidence that these have a higher possibility of success than mono-target therapy, and multi-target therapy should remain the most attractive avenue for future treatment strategies. In this article, we attempt to provide evidence for the role of small interfering RNA in multi-target therapy of cancer.
Animals ; Genetic Therapy ; Humans ; Neoplasms ; genetics ; therapy ; RNA Interference ; RNA, Small Interfering ; genetics ; therapeutic use ; Radiation Tolerance

Antisense RNA molecule represents a unique type of DNA transcript that comprises 19-23 nucleotides and is complementary to mRNA. Antisense RNAs play the crucial role in regulating gene expression at multiple levels, such as at replication, transcription, and translation. In addition, artificial antisense RNAs can effectively regulate the expression of related genes in host cells. With the development of antisense RNA, investigating the functions of antisense RNAs has emerged as a hot research field. This review summarizes our current understanding of antisense RNAs, particularly of the formation of antisense RNAs and their mechanism of regulating the expression of their target genes. In addition, we detail the effects and applications of antisense RNAs in antivirus and anticancer treatments and in regulating the expression of related genes in plants and microorganisms. This review is intended to highlight the key role of antisense RNA in genetic research and guide new investigators to the study of antisense RNAs.
Animals ; Antineoplastic Agents/therapeutic use* ; Antiviral Agents/therapeutic use* ; Gene Expression Regulation ; Genetic Research ; Humans ; MicroRNAs/physiology* ; RNA, Antisense/physiology* ; RNA, Long Noncoding/physiology* ; RNA, Small Interfering/physiology*

OBJECTIVE: To observe the mutation and expression of TCF3 gene in Burkitt's lymphoma (BL), and explore its effect on the proliferation of BL cells and clinical efficacy and prognosis. METHODS: The mutation and expression of TCF3 in tumor tissues from BL patients were observed by the second-generation sequencing and real-time quantitative PCR. The proliferation and apoptosis of lymphoma cells after TCF3 knocked down were observed by siRNA interference technique and CCK-8 method. Survival analysis was used to observe the relationship between TCF3 mutation and the treatment efficacy and prognosis of BL patients. RESULTS: There were high frequency mutation rate (mutation rate was 23.7%) and high expression of TCF3 in BL patients. After TCF3 knocked down, cell proliferation was inhibited and apoptosis was promoted. In TCF3-siRNA group and control group, the cell proliferation rate at 48 h was (50.2±5.9)% and (96.6±11.4)%, and apoptosis rate was 30.1% and 1.5%, respectively, which showed significantly different between the two groups (P<0.001, P=0.005). The complete remission rate of patients with TCF3 mutation was low. The complete remission rate of mutant group and wild-type group was 44.4% and 82.8%, respectively (P=0.023). The 2-year progression-free survival rate and overall survival rate of the patients with TCF3 mutation was 55.6% and 61.0%, respectively, which was lower than 83.2% and 85.2% of the patients without mutation, but the differences were not statistically significant. CONCLUSION There are mutation and abnormal expression of TCF3 in patients with BL. Patients with TCF3 mutations have low remission rate and poor prognosis.
Apoptosis ; Basic Helix-Loop-Helix Transcription Factors/therapeutic use* ; Burkitt Lymphoma/genetics* ; Humans ; Prognosis ; RNA, Small Interfering/therapeutic use* ; Sincalide/therapeutic use*

OBJECTIVETo evaluate the possibility of short interfering RNA (siRNA) inhibiting Coxsackievirus B3 (CVB3) infection in vitro, and discover the mechanism initially.

METHODSWe obtained proper effective dosage of siRNA by observing cytopathic effect (CPE). Estimate its antiviral activities and its pathway of siRNA by Western Blot assay and RT-PCR.

RESULTSResults showed that siRNA-3753 can be effectively transfected into HeLa cells, we can achieve a high transfection efficiency up to 98.77% and its effect can last for 48 h stably in cells. 0.6 micromol/L siRNA-3753 got a high inhibiting effect of virus and didn't show any toxicity to cells. So we consider this concentration as the experimental concentration. siRNA-3753 can debase virus reproduction. The antiviral effect is sequence-specific and is not attributable to either interferon or the interferon response effectors protein kinase R (PKR).

CONCLUSIONThe data confirmed that siRNA can effectively inhibit CVB3 infection in vitro, its antivirus effect was gained from specific debase of virus genome.

Coxsackievirus Infections ; therapy ; virology ; Enterovirus B, Human ; genetics ; metabolism ; HeLa Cells ; Humans ; RNA Interference ; RNA, Small Interfering ; genetics ; therapeutic use ; RNA, Viral ; genetics

Animals ; Gene Silencing ; physiology ; Gene Targeting ; Genetic Therapy ; methods ; Genomics ; Humans ; RNA Interference ; RNA, Small Interfering ; genetics ; therapeutic use ; RNA-Induced Silencing Complex

Animals ; Antineoplastic Agents ; therapeutic use ; Gene Silencing ; Genetic Therapy ; methods ; Humans ; MicroRNAs ; antagonists & inhibitors ; therapeutic use ; Neoplasms ; genetics ; therapy ; RNA Interference ; physiology ; RNA, Small Interfering ; antagonists & inhibitors ; therapeutic use ; RNA-Induced Silencing Complex ; metabolism

Animals ; Hepacivirus ; genetics ; Hepatitis B ; therapy ; Hepatitis B virus ; genetics ; Hepatitis C ; therapy ; Humans ; Mice ; RNA Interference ; RNA, Small Interfering ; therapeutic use ; Virus Replication